Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surrozen (SRZN) Cash & Equivalents (2021 - 2025)

Surrozen (SRZN) has 5 years of Cash & Equivalents data on record, last reported at $81.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 162.16% year-over-year to $81.3 million; the TTM value through Sep 2025 reached $81.3 million, up 162.16%, while the annual FY2024 figure was $34.6 million, 4.1% down from the prior year.
  • Cash & Equivalents reached $81.3 million in Q3 2025 per SRZN's latest filing, down from $90.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $101.6 million in Q1 2025 and bottomed at $14.3 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $39.8 million, with a median of $33.1 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: tumbled 58.21% in 2022, then skyrocketed 272.46% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $33.1 million in 2021, then dropped by 25.39% to $24.7 million in 2022, then skyrocketed by 45.98% to $36.0 million in 2023, then decreased by 4.1% to $34.6 million in 2024, then surged by 135.21% to $81.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $81.3 million in Q3 2025, $90.4 million in Q2 2025, and $101.6 million in Q1 2025.